# Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy

> **NCT05526703** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 108 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** D064, D701, placebo of D012
- **DRUG:** D012, placebo of D064, placebo of D701

## Key facts

- **NCT ID:** NCT05526703
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-28
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526703, "Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05526703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*